Alumis Inc.
ALMS
주식 순위
#10173
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
주가
$6.41
마지막 동기화: 2026-10-19
시가총액
$830.25M
변동 (1일)
4.81%
변동 (1년)
182.57%
국가
US
거래 Alumis Inc. (ALMS)
카테고리
Healthcare
Alumis Inc. (ALMS)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 0.49
Alumis Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0.49입니다. 2023년 말 기준 P/B 비율은 0.80였습니다.
Alumis Inc.의 P/B 비율 기록 (2021 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.49 | -27.66% |
| 2024 | 0.68 | -14.79% |
| 2023 | 0.80 | -36.26% |
| 2022 | 1.25 | -114.32% |
| 2021 | -8.75 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | 1,170.79% |
US
|
|
| 13.2547 | 2,594.59% |
US
|
|
| 4.208 | 755.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 1,156.84% |
NL
|
